Navigation Links
BioInformatics LLC Multi-Sponsor Market Report – In-depth Exploration of the U.S. Market for Biosimilar Drugs
Date:2/21/2013

Arlington, VA (PRWEB) February 21, 2013

The delivery of more cost-effective healthcare has become a worldwide challenge as the costs associated with healthcare continue to increase, driven by changing demographics, societal expectations and advances in medical technology. The introduction of alternative versions of biologic products, also known as biosimilars, into the United States market has been gaining increasing visibility as patents for many agents are nearing expiration and as the FDA moves closer to establishing a regulatory pathway for these agents. For these reasons, BioInformatics LLC is opening sponsorship opportunities for an in-depth report in this space: Manufacture of Biosimilar Drugs for the U.S. Market: Defining the Market Opportunity for Life Science Suppliers.

As scientific and analytical instrument manufactures seek to explore new markets to offset slower growth and reduced funding in academic research, attention turns to the potential for revenues generated by the pending authorization for pharmaceutical and biopharmaceutical companies to move forward with the development and commercialization of biosimilar drugs in the U.S.

The process is complicated, and the onus is on the drug manufacturers to prove that the biosimilar drugs have a similar structure and function as the original branded drugs. As with a generic small-molecule drug, biosimilars will ostensibly be less costly for the consumer and therefore enjoy a sizable demand. However, long before this nascent family of drugs can reach the market, biopharmaceutical companies will be required to ramp up their capacity to conduct the FDA-required analysis.

Or will they? Are labs going to need new instruments, or will they be able to conduct this research with their currently installed equipment? Will new features be required to achieve the biophysical characteristics and biological function of the reference standard biological drug? Which molecules will be targeted? Will new drugs be developed that go beyond the efficacy of the branded version?

These are questions that suppliers are asking and that will be addressed in the syndicated report: Manufacture of Biosimilar Drugs for the U.S. Market: Defining the Market Opportunity for Life Science Suppliers. Comprised of 25 interviews from U.S. pharmaceutical/CRO companies and 25 interviews with EU pharmaceutical/CRO companies—to include both R&D and regulatory personnel—this report will be an in-depth exploration of what the decision-makers are saying about what’s on the near horizon for biosimilar drug development.

The report is scheduled to release on May 31, 2013. The deadline to become a sponsor for this research is March 8, 2013. Click here for a more complete description of the report.

ABOUT BIOINFORMATICS LLC

BioInformatics LLC is the premier research and advisory firm serving the life science industry. By leveraging our professional social network of more than 71,000 life scientists, we have supported more than 500 companies and provided insights that lead to better business decisions. Our assignments include assessing the size and attractiveness of markets, optimizing product configurations and pricing, validating corporate acquisitions, measuring customer loyalty, and evaluating brand strength and positioning.

Read the full story at http://www.prweb.com/releases/2013/2/prweb10453683.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Global Bioinformatics Industry
2. Japan Bioinformatics Announces Study on Leading Mapping Tools for DNA Mutation Discovery
3. BioInformatics LLC New Product Launch – RateMyProduct, a Quick Turnaround Product Assessment Tool for Life Science Suppliers
4. BioInformatics LLC New Market Report – Opportunities for New Players in the Growing Stem Cell Market
5. BioInformatics LLC Webcast – The Life Science Product Manger’s Toolkit
6. BioInformatics LLC New Market Report – Best Practices Guide for Advertising to Life Scientists
7. Japan Bioinformatics Announces the Release of their Simbiot® Time Course Analysis ‘How-To’ Guide
8. MarketsandMarkets: Lung Cancer Drugs Market in G7 Countries Worth $13 Billion by 2020
9. Sequenom Announces Participation at the Lazard Capital Markets 8th Annual Healthcare Conference
10. Organovo to Present at Lazard Capital Markets 8th Annual Healthcare Conference
11. Pharmasset to Present at the Lazard Capital Markets Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... CA (PRWEB) , ... December 01, 2016 , ... ACEA ... from its Phase I/II clinical trials for AC0010 at the World Conference on Lung ... to providing an update on the phase I/II clinical trials for AC0010 in patients ...
(Date:12/2/2016)... KING OF PRUSSIA, PA (PRWEB) , ... December 01, 2016 , ... ... clinical research is through industry-wide collaboration, standardization and a beautiful technology experience. All three ... which convened more than 100 clinical trial leaders from over 40 sponsor, CRO and ...
(Date:12/2/2016)... -- The immunohistochemistry (IHC) market is projected to ... 7.3% during the forecast period of 2016 to 2021 dominated by ... for the largest share of immunohistochemistry (IHC) market, by end user. ... , , ... spread across 225 pages, profiling 10 companies and supported with 181 ...
(Date:11/30/2016)... , Nov. 30, 2016 /PRNewswire/ - Portage Biotech ... Securities Exchange: PBT.U), is excited to announce the ... focused on developing preclinical ophthalmology assets through proof ... potent anti-inflammatory created by Portage Pharmaceuticals Limited and ... with ocular surface and anterior segment diseases. This ...
Breaking Biology Technology:
(Date:11/22/2016)... , Nov. 22, 2016   MedNet Solutions , ... entire spectrum of clinical research, is pleased to announce ... LiveWire Healthcare and Life Sciences Awards as "Most ... off an unprecedented year of recognition and growth for ... over 15 years. iMedNet ™ ...
(Date:11/17/2016)... Market Watch: Primarily supported by ownership types; Private ... market is to witness a value of US$37.1 billion by ... Annual Growth Rate (CAGR) of 10.75% is foreseen from ... North America is not way behind ... at 9.56% respectively. Report Focus: The ...
(Date:11/15/2016)...  Synthetic Biologics, Inc. (NYSE MKT: SYN), a ... gut microbiome, today announced the pricing of an ... common stock and warrants to purchase 50,000,000 shares ... the public of $1.00 per share and accompanying ... offering, excluding the proceeds, if any from the ...
Breaking Biology News(10 mins):